# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Maxim Group analyst Jason McCarthy downgrades Cyclo Therapeutics (NASDAQ:CYTH) from Buy to Hold.
Ascendiant Capital analyst Lucas Ward maintains Cyclo Therapeutics (NASDAQ:CYTH) with a Buy and lowers the price target from...
HC Wainwright & Co. analyst Swayampakula Ramakanth downgrades Cyclo Therapeutics (NASDAQ:CYTH) from Buy to Neutral and l...
On consummation of the merger, Rafael will issue Class B shares to Cyclo Therapeutics' shareholders, based on an exchange r...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Cyclo Therapeutics (NASDAQ:CYTH) with a Buy and maintains ...